ADR Biomedical HoldingsTSE:3750 -1.23%30 Current Ratio is 1.55 as of Mar. 2026, which is 46% below its 10-year median of 2.85. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.42 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,409 Biotechnology companies, ADR Biomedical Holdings ranks worse than 74.95% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ADR Biomedical Holdings's current ratio for the quarter that ended in Mar. 2026 was 1.55.
ADR Biomedical Holdings has a current ratio of 1.55. It generally indicates good short-term financial strength.
The historical rank and industry rank for ADR Biomedical Holdings's Current Ratio or its related term are showing as below:
TSE:3750'
s Current Ratio Range Over the Past 10 Years
Min: 1.05 Med: 2.85 Max: 23.3
Current: 1.55
During the past 13 years, ADR Biomedical Holdings's highest Current Ratio was 23.30. The lowest was 1.05. And the median was 2.85.
TSE:3750's Current Ratio is ranked worse than 74.95% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs TSE:3750: 1.55
ADR Biomedical Holdings (TSE:3750) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ADR Biomedical Holdings Current Ratio Related Terms
ADR Biomedical Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a Current Ratio of 1.55 as of Mar. 2026. This is 46% below median its historical median of 2.85. Over the past decade, ADR Biomedical Holdings' Current Ratio has ranged from 1.05 to 23.30. According to the industry distribution chart, ADR Biomedical Holdings ranks #1056 out of 1409 companies in the Biotechnology industry, placing it in the top 74.9%.
Is ADR Biomedical Holdings' Current Ratio too high?
ADR Biomedical Holdings' current Current Ratio of 1.55 is 46% below median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 23.30. The Biotechnology industry median Current Ratio is 3.89. ADR Biomedical Holdings' value of 1.55 is 60.2% below this industry median. Based on the distribution chart, ADR Biomedical Holdings ranks #1056 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #1056 out of 1409 companies for Current Ratio. This places ADR Biomedical Holdings in the lower half of its industry. The industry median Current Ratio is 3.89. ADR Biomedical Holdings' value of 1.55 is 60.2% below this benchmark. Historically, ADR Biomedical Holdings' own Current Ratio has ranged from 1.05 to 23.30 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 3.89, ADR Biomedical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADR Biomedical Holdings's current Current Ratio of 1.55 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current Current Ratio is 1.55, which is 46% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current Current Ratio is 1.55, which is 46% below median its 10-year median of 2.85 and 60.2% below the Biotechnology industry median of 3.89. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Current Ratio is 1.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Current Ratio: 1.55 (46% below median its 10-year median of 2.85)
GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
Industry Position: 60.2% below the Biotechnology median (#1056 of 1409)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score
Get the complete analysis for TSE:3750
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
